Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- MHLW Panel Approves 18th Edition of Japanese Pharmacopoeia; 33 New Products Added
October 7, 2020
- Label Revisions Ordered for Takecab, 2 Other Drugs
October 7, 2020
- MHLW Lays Out Compliance Guidelines for Manufacturers; Introduction Planned in August 2021 under Amended PMD Law
October 6, 2020
- Scrap Income Limit for Fertility Treatment Subsidies: LDP Lawmakers
October 5, 2020
- MHLW to Draft Guidelines by Year-End on Use of Patient Registry Data in Drug Filing
October 5, 2020
- PMDA to Offer Free Consultations for COVID-19 Vaccines
October 2, 2020
- MHLW Bankrolls 3 Projects Aiming to Manufacture Key APIs, Raw Materials in Japan
October 2, 2020
- MHLW’s Review Division Head Stresses Evidence-Based Approval for Coronavirus Vaccines
October 1, 2020
- Metformin Cancer Risk Acceptable at 1 in 550,000 Patients: NIHS Assessment
October 1, 2020
- MHLW Submits FY2021 Budget, Personnel Requests
October 1, 2020
- Priority Shots for Seasonal Flu Begin for Elderly, Other High-Risk People
October 1, 2020
- Rotavirus Vaccines Now Covered by National Immunization Program
October 1, 2020
- Independent Monitoring Panel Kicks Off Discussions; MHLW-PMDA Collaboration, Ad Rules among Topics
September 30, 2020
- Kentaro Enomoto to Take Over Councilor Post for Health Insurance on October 1: MHLW
September 30, 2020
- MHLW Urges Healthcare Stakeholders to Comply with Distribution Guidelines Even in COVID-19 Outbreak
September 30, 2020
- MHLW Pharma Bureau Seeks 13 Billion Yen for FY2021, Eyes Vaccine Quality Assurance Guidance in COVID-19 Quota
September 29, 2020
- MHLW Seeks Nearly 33 Trillion Yen in Unusual Budget Request for FY2021; COVID-19 Quota Yet to Come
September 29, 2020
- MHLW’s Health Policy Bureau Requests New Budgets to Forge Clinical Trial Network in Asia
September 29, 2020
- Coronavirus Panel OKs Interim Report on COVID-19 Vaccination, Sorts Out Roles of Central, Local Govts
September 29, 2020
- MHLW Economic Affairs Chief Not Optimistic about Reaching 80% Generic Target
September 28, 2020
ページ
Japan’s health and finance ministers agreed late last year to go ahead with an “off-year” drug price revision in FY2027,…
The Japanese healthcare sector is experiencing rapid growth, demanding a highly skilled and diverse workforce. However, finding and attracting the best talent in this competitive market presents significant challenges.Enter AI. With the rise of AI-powered tools, healthcare organizations can revolutionize…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…